EWP
REGN icon

Elevation Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Elevation Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.9K Buy
17
+1
+6% +$756 ﹤0.01% 811
2026
Q2 		$9.98K Buy
16
+4
+33% +$2.72K ﹤0.01% 809
2026
Q1 		$9.27K Buy
12
+1
+9% +$766 ﹤0.01% 530
2025
Q4 		$8.49K Buy
11
+5
+83% +$3.4K ﹤0.01% 515
2025
Q3 		$3.37K Buy
+6
New +$3.39K ﹤0.01% 544

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return
JC
Jacobs & Co San Francisco, California $1.16B AUM 34.03% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Elevation Wealth Partners's REGN Position: Q3 2026 in Review

Elevation Wealth Partners increased its Regeneron Pharmaceuticals (REGN) stake by 6.3% in Q3 2026, buying an estimated $756 and bringing the position to 17 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #811.

Elevation Wealth Partners first reported a position in REGN in Q3 2025 and has held it in 5 quarters since. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Elevation Wealth Partners held 17 shares of Regeneron Pharmaceuticals worth $12.9K as of Q3 2026.
  • Elevation Wealth Partners bought 1 Regeneron Pharmaceuticals share in Q3 2026, an estimated $756.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #811 holding.
  • Elevation Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.